

Underexpression of PPAR γ is associated with aneuploidy and lower differentiation of thyroid tumours of follicular origin

CARLA ESPADINHA¹, ANTÓNIO E. PINTO² and VALERIANO LEITE^{1,3}

¹Molecular Endocrinology Group, Molecular Pathobiology Research Centre (CIPM), ²Department of Morphologic Pathology, Portuguese Institute of Oncology of Lisbon Francisco Gentil E.P.E.;

³Faculty of Medical Sciences, New University of Lisbon, Lisbon, Portugal

Received January 28, 2009; Accepted April 16, 2009

DOI: 10.3892/or_00000516

Abstract. Peroxisome proliferator-activated receptor γ (PPAR γ) gene is a nuclear receptor that is involved in thyroid tumourigenesis. Recently, our group has shown that follicular carcinomas underexpressing PPAR γ protein are more prone to develop distant metastases, to invade locally, to present poorly differentiated areas and to persist after surgery. Aneuploidy is also observed in some thyroid tumours, particularly in the more advanced cases. The aim of the present study was to investigate the association of PPAR γ expression with the degree of differentiation and ploidy status of benign and malignant thyroid neoplasias. DNA cytometric studies, ploidy and S-phase fraction (SPF) determination, and quantitative RT-PCR analysis of molecular markers specific for thyroid follicular cells, namely Tg (thyroglobulin), TSHR (TSH receptor) and NIS (Na⁺/I⁻ symporter) were compared between thyroid lesions with positive or negative PPAR γ protein expression. We observed that PPAR γ -negative tissues expressed lower levels of Tg mRNA [4.66×10^6 a.u. (arbitrary units) $\pm 1.49 \times 10^6$], and were more frequently aneuploid

(36%), and presented higher SPF ($3.1\% \pm 0.4$) than PPAR γ -positive samples (Tg mRNA = 2.54×10^7 a.u. $\pm 9.72 \times 10^6$, $P=0.0006$; aneuploidy=8%, $P=0.0031$; SPF= $2.2\% \pm 0.2$, $P=0.0430$). A similar trend was also observed for TSHR and NIS mRNA, although not reaching statistical significance. This study showed that underexpression of PPAR γ is associated with poor tumour differentiation, aneuploidy and higher cell proliferative activity. Therapies designed to modulate expression of PPAR γ may have an impact on the growth of thyroid neoplasias.

Introduction

The molecular genetics underlying thyroid carcinogenesis is not fully understood. Recently, rearrangements between PAX8 and PPAR γ (peroxisome proliferator-activated receptor γ) genes were associated with follicular thyroid carcinomas (FTCs) and adenomas (FTAs) (1-3). PPAR γ is a nuclear receptor that participates in a wide range of cellular processes, such as adipocyte differentiation, lipid storage, insulin sensitization (4-6), cell cycle control, inflammation, atherosclerosis, apoptosis and carcinogenesis (7). PPAR γ is activated by natural ligands (e.g., prostaglandin J2 and fatty acids derivatives) or by synthetic ligands (thiazolidinediones). These ligands induce apoptosis and exert anti-proliferative effects on several carcinoma cell lines and inhibit the growth of thyroid carcinoma cells *in vivo* (8-11). In different types of cancer, several studies have shown that, compared to their normal counterparts, tumours can present either overexpression (12,13), underexpression (14) or similar expression of PPAR γ (15). Studies in human colon carcinomas, with monoallelic PPAR γ mutations, indicated that colon cancer is associated with loss-of-function mutations in PPAR γ (16). In addition, PAX8PPAR γ fusion protein, resulting from the t(2;3)(q13;p25) translocation between PAX8 and PPAR γ genes, is present in a significant proportion of thyroid follicular tumours (1).

Aneuploidy is one of the most frequent genetic abnormalities found in cancer. It results from full or partial aneusomies in which the copy number of entire chromosomes or chromosomal subregions is altered. Aneuploidy *per se* has been proposed to be an early and genetically destabilizing force in cancer development (17), but the

Correspondence to: Dr Valeriano Leite, Molecular Endocrinology Group, CIPM, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Rua Professor Lima Basto, 1099-023 Lisboa, Portugal
E-mail: vleite@ipolisboa.min-saude.pt

Abbreviations: PPAR γ , peroxisome proliferator-activated receptor γ ; FTC, follicular thyroid carcinoma; FTA, follicular thyroid adenoma; PDTC, poorly-differentiated thyroid carcinoma; PTC, papillary thyroid carcinoma; NH, nodular hyperplasia; IHC, immunohistochemistry; SPF, S-phase fraction; Tg, thyroglobulin; TSHR, TSH receptor; NIS, Na⁺/I⁻ symporter; QRT-PCR, quantitative RT-PCR; NT, normal thyroid tissue; ATC, anaplastic thyroid carcinoma; PBS, phosphate-buffered saline; CV, coefficient of variation; SEM, standard error of the mean; a.u., arbitrary units; RB, retinoblastoma

Key words: PPAR γ , aneuploidy, thyroid, thyroglobulin, TSH receptor, Na⁺/I⁻ symporter

molecular mechanisms underlying aneuploidy are poorly understood. In thyroid lesions, aneuploidy is mostly found in poorly-differentiated thyroid carcinomas (PDTCs), is rare in papillary thyroid carcinomas (PTCs), being observed in a range of 10-57% of follicular tumours (18), and in 10-22% of nodular hyperplasias (NHs) (19-21).

In a previous study (22), we demonstrated that follicular carcinomas that do not express PPAR γ protein by immunohistochemistry (IHC) are more prone to develop distant metastases, to invade locally, to present poorly differentiated areas and to persist after surgery. These results suggest an association between underexpression of PPAR γ and a less differentiated phenotype. Aiming to investigate this hypothesis, we determined the ploidy status, S-phase fraction (SPF) and the mRNA expression of molecular markers of thyroid follicular cells [Tg (thyroglobulin), TSHR (TSH receptor) and NIS (Na⁺/I⁻ symporter)], by quantitative RT-PCR (QRT-PCR), in benign and malignant thyroid tissues with positive or negative PPAR γ staining.

Materials and methods

Materials. In a previous study by our group (22), PPAR γ protein was detected by IHC in 77% of normal thyroid tissues (NTs), 71% of NHs ($P>0.05$, vs. NT), 62% of FTAs ($P>0.05$, vs. NT), 53% of FTCs ($P=0.03$, vs. NT) and 49% of PTCs ($P=0.01$, vs. NT). All PDTCs/ATC were negative ($P<0.0001$, vs. normal thyroid tissue). Positive staining was usually faint or moderate (in tissues negative for the PAX8/PPAR γ rearrangement). From this published series, we selected cases ($n=95$), from which frozen samples were available, for RNA extraction and quantitative analysis of thyroid specific transcripts. These cases were: 10 NHs, 29 FTAs, 9 FTCs, 37 PTCs (15 classic, 14 follicular, 3 oxyphilic, 3 tall cells and 2 cribriform), 9 PDTCs and 1 anaplastic thyroid carcinoma (ATC). The material was retrieved from the files of the Portuguese Institute of Oncology Francisco Gentil, Lisboa, and institutional ethics guidelines were strictly followed. Samples were immediately frozen at time of surgery to subsequent RNA extractions and DNA flow cytometric analysis, and were also embedded in paraffin for immunohistochemistry. Haematoxylin- and eosin-stained sections were evaluated histologically by pathologists to classify the tumours according to the 2004 World Health Organization Classification of Tumours of Endocrine Organs.

RNA extraction and cDNA synthesis. Total RNA was isolated from frozen tissues by TRIzol reagent (Invitrogen, Paisley, UK), according to the manufacturer's protocol. RNA was quantified by UV spectrophotometry (optical density measured at 260 nm). Complementary DNA (cDNA) was synthesized from 1 or 2 μ g [for quantitative real-time PCR (QRT-PCR)] of total RNA at 37°C for 90 min, using oligo(dT) primers (Invitrogen) and reverse transcriptase (Superscript II, Invitrogen).

Detection of PAX8PPAR γ fusion gene. PAX8PPAR γ fusion gene was analysed in the entire series by RT-PCR ($n=80$) or FISH ($n=4$), and the remaining cases ($n=11$) by both techniques, as described previously (2,22). All the samples

were negative for the PAX8PPAR γ fusion gene. This was an important criterion used for sampling selection, since the presence of the PAX8PPAR γ fusion protein increases the expression of wild-type PPAR γ protein (anti-PPAR γ antibody used in this study recognizes PPAR γ regions common to both PAX8PPAR γ fusion protein and to wild-type PPAR γ protein).

QRT-PCR. The mRNA expression levels of Tg, NIS and TSHR were quantified using TaqMan probes for Tg and NIS analysis and SYBR Green dye for TSHR analysis, on an ABI PRISM 7900 HT Sequence Detection Systems (Applied Biosystems, Foster City, CA, USA). To analyze the mRNA expression levels of Tg and NIS by TaqMan probes, specific primers and the probes were selected from the Assay-on-demand products [P/N 4331182; Hs00794359_m1 (Tg), Hs00166567_m1 (NIS); Applied Biosystems]. In order to normalize the differences in the amount of total cDNA used in each reaction, we performed the amplification of GAPDH cDNA as endogenous control (Pre-Developed TaqMan Assay Reagents; P/N 4326317E; Applied Biosystems). Gene expression assays have a FAM (Tg and NIS) or a VIC (GAPDH) reporter dye at 5'-end of the TaqMan MGB probe, and a non-fluorescent quencher at the 3'-end of the probe. To analyse the mRNA expression level of TSHR by SYBR Green dye, we used the following primers: TSHR F (5'-GAA CTGATAGCAAGAAACACCTGG-3') and TSHR R (5'-GTA TCCTGGAAGTGGACTTTT-3') for TSHR gene and PGK F (5'-CAGTTTGGAGCTCCTGGAAG-3') and PGK R (5'-TGC AAATCCAGGGTGCAGTG-3') for PGK-1 gene (23).

cDNA of each sample was synthesized from 2 μ g of RNA, as described above. Quantitative RT-PCR was performed in a total reaction volume of 25 μ l containing 1X TaqMan Universal PCR Master Mix (P/N 4304437; Applied Biosystems), 1X Assays-on-demand Gene Expression Assay Mix and 2 μ l of cDNA diluted in RNase-free water, or 1X SYBR Green PCR Master Mix (P/N 4309155; Applied Biosystems), 10 pmol of each primer and 2 μ l of cDNA diluted in RNase-free water. All reactions were performed in a 96-well reaction plate (MicroAmp Optical 96-Well Reaction Plate, Applied Biosystems). Samples were heated for 2 min at 50°C, followed by 10 min at 95°C and amplified for 50 cycles of 15 sec at 95°C and 1 min at 60°C. SYBR Green assays were followed by a dissociation curve analysis. cDNA from Nthy-ori 3-1 cell line (SV40 large-T-antigen immortalized normal human differentiated thyroid cells - European Collection of Cell Culture, Wiltshire, UK) was serially diluted in dH₂O and amplified in parallel to establish a standard curve for relative quantification. Nthy-ori cell cDNA was also used as calibrator for determining the relative expression of Tg, NIS and TSHR genes. For each sample, the amount of target RNA was normalised to the standard curve, then normalised to the endogenous control RNA expression and then to the calibrator. All quantitative real-time RT-PCR experiments, including a control with no template, were performed in triplicate.

The mRNA expression levels for Tg were analysed in 31 samples (20 FTAs, 7 FTCs and 4 PTCs), for TSHR in 29 samples (20 FTAs, 5 FTCs and 4 PTCs), and for NIS in 20 samples (9 FTAs, 7 FTCs and 4 PTCs).

DNA flow cytometry. Flow cytometric analysis was performed in representative tumour tissue frozen at -80°C at time of surgery. Tissue samples were disaggregated mechanically using sterile surgery blades in phosphate-buffered saline (PBS) in a Petri plaque. Then, the cell suspension was washed twice and cells were counted in a Bürker's counting chamber. To perform the DNA-specific staining (24), cells were treated with a solution of ribonuclease 1 mg/ml (Sigma-Aldrich, St. Louis, USA) in PBS, for digestion of double-stranded RNA, and a non-ionic detergent Nonidet P40 0.05% (Sigma-Aldrich), for cell lysis. Nuclei were stained with propidium iodide (Sigma), $50\text{ }\mu\text{g/ml}$ in Tris- MgCl_2 , for 1 h at 4°C in the dark. After filtration with a $55\text{-}\mu\text{m}$ nylon mesh, the stained cell nuclei were analysed on an Epics Profile II (Flow cytometer, Coulter Electronics, Hialeah, FL, USA) equipped with a 488-nm argon-ion laser. The instrument was aligned daily and considered calibrated when the coefficients of variation (CVs) of standard fluorescent microspheres were below 2% (DNA-Check, Coulter). At least 20000 nuclei were acquired for each case and the results were recorded on a single parameter 256 channel fluorescence histogram.

Cell cycle analysis of DNA histograms was performed with the Multicycle program (Phoenix Flow Systems, San Diego, CA, USA), based on the mathematical method described by Dean and Jett (25) which includes a multiple option cell cycle fitting that automatically determines the DNA index. The DNA ploidy pattern of tumours was expressed by the dichotomy diploid (one G_0/G_1 peak, DNA index = 1.0) vs. aneuploid (one or more abnormal populations, DNA index $\neq 1.0$). The internal reference standard was formed by non-malignant diploid cells (fibroblasts, lymphocytes, normal epithelial cells) mixed with the analysed sample. The histograms that presented CVs above 8% were rejected. The S-phase fraction (SPF), a measure of the tumour proliferative activity, was determined according to a polynomial model and corresponds to the percentage of cells in S-phase of the cell cycle. Technical reasons related to excess of background debris, non-specific fluorescence or overlapping of populations impaired the SPF evaluation in 24 of 95 (25.3%) cases.

Cytometric analysis for ploidy was performed in 95 samples (10 NHs, 29 FTAs, 9 FTCs, 37 PTCs, 9 PDTs and 1 ATC), and S-phase fraction was investigated in 71 samples (8 NHs, 20 FTAs, 4 FTCs, 31 PTCs and 8 PDTs).

Statistical analysis. The comparison of Tg, TSHR and NIS mRNA expression levels between PPAR γ protein negative and positive tissues was performed by the Mann-Whitney test. DNA ploidy and SPF were analysed in the different thyroid histotypes with the χ^2 test, and one-way ANOVA test (with the Dunnett's Multiple Comparison test), respectively. To correlate SPF with ploidy status and PPAR γ protein expression we used the unpaired t-test (two-tailed). To correlate the PPAR γ protein expression with ploidy, we used the Fisher's exact test (two-tailed). Non-parametric tests were used when the data were not normally distributed. P-values ≤ 0.05 were considered significant. Statistical analysis was performed using GraphPad Prism statistical software (San Diego, CA, USA). All graphs with error bars indicate means \pm standard error of the mean (SEM).




Figure 1. mRNA expression of (A) Tg, (B) TSHR and (C) NIS in PPAR γ -negative and PPAR γ -positive thyroid tumours (FTAs, FTCs and PTCs), as assessed by real-time RT-PCR, using TaqMan probes (Tg and NIS) and SYBR Green dye (TSHR). Tg, TSHR and NIS mRNA levels were normalized to values of GAPDH (Tg and NIS) or PGK-1 (TSHR) housekeeping genes and to a calibrator (Nthy-ori cells). Graphs with error bars indicate mean value \pm SEM. Significant differences between PPAR γ -negative and PPAR γ -positive cases are indicated.

Results

Correlation between the expression of the PPAR γ protein and the expression of Tg, TSHR and NIS mRNAs. The mean Tg mRNA expression level was lower in PPAR γ -negative [4.66×10^6 a.u. (arbitrary units) $\pm 1.49 \times 10^6$; n=17] than in PPAR γ -positive cases (2.54×10^7 a.u. $\pm 9.72 \times 10^6$; n=14; P=0.0006) (Fig. 1A). This difference in Tg mRNA expression was also statistically significant within the group of FTAs (PPAR γ -, 4.06×10^6 a.u. $\pm 1.58 \times 10^6$; n=10 vs. PPAR γ +, 3.24×10^7 a.u. $\pm 1.32 \times 10^7$; n=10; P=0.0021). Although not

Table I. Ploidy analysis in benign and malignant thyroid lesions.

Histotype (n)	Ploidy	
	Diploid (%)	Aneuploid (%)
NH (n=10)	8 (80)	2 (20)
FTA (n=29)	20 (69)	9 (31)
FTC (n=9)	7 (78)	2 (22)
PTC (n=37)	33 (89)	4 (11)
PDTC/ATC (n=10)	3 (30)	7 (70)

χ^2 test, $P=0.0039$ (frequency of aneuploidy vs histotype); n, number of samples.

Table II. S-phase cell fraction in benign and malignant thyroid lesions.

Histotype (n)	Range (%)	S-phase cell fraction (mean (%) \pm SEM)	P-value ^a
NH (n=8)	1.2-5.7	2.3 \pm 0.5	<0.01
FTA (n=20)	0.3-4.8	2.3 \pm 0.2	<0.01
FTC (n=4)	0.9-7.4	3.7 \pm 1.5	n.s.
PTC (n=31)	0.8-4.2	2.3 \pm 0.2	<0.01
PDTC (n=8)	1.9-11.7	5.4 \pm 1.2	-

One-way ANOVA test, $P<0.0001$. ^aDunnett's Multiple Comparison test, each histotype vs. PDTCs; n, number of samples; n.s., non-significant.

statistically significant, we observed that PPAR γ -negative tumours expressed lower levels of TSHR and NIS mRNA than PPAR γ protein positive cases (TSHR mRNA: PPAR γ -, 1.61×10^9 a.u. \pm 7.14×10^8 ; n=16 vs. PPAR γ +, 2.21×10^9 a.u. \pm 9.99×10^8 ; n=13; $P=0.2279$) (NIS mRNA: PPAR γ -, 2.99×10^2 a.u. \pm 2.90×10^2 ; n=11 vs. PPAR γ +, 3.79×10^2 a.u. \pm 1.98×10^2 ; n=9; $P=0.1287$) (Fig. 1B and C).

Ploidy and SPF analyses. The results obtained in the ploidy and SPF analyses of thyroid lesions are summarised in Tables I and II. Aneuploidy was significantly higher ($P=0.0039$) in PDTCs (70%) than in the other thyroid lesions. SPF was higher in PDTCs ($5.4\% \pm 1.2$) than in NHs ($2.3\% \pm 0.5$; $P<0.01$), FTAs ($2.3\% \pm 0.2$; $P<0.01$), PTCs ($2.3\% \pm 0.2$; $P<0.01$) or FTCs ($3.7\% \pm 1.5$; n.s.). The differences in SPF values between FTCs and the other histotypes were not statistically significant ($P>0.05$, Dunnett's Multiple Comparison test). The highest SPF values were observed in 2 PDTCs (11.7 and 9.3%) and in 1 FTC (7.4%). Overall, aneuploid lesions presented higher SPF than diploid lesions ($5.7\% \pm 0.8$; n=11 vs. $2.2\% \pm 0.1$ n=60; $P<0.0001$) (Fig. 2).




Figure 2. Correlation between ploidy status and the S-phase fraction of thyroid lesions. Aneuploid cases presented higher SPF than diploid cases ($P<0.0001$). Graph with error bars indicate mean value \pm SEM.




Figure 3. Correlation between S-phase fraction and PPAR γ protein expression of thyroid lesions. PPAR γ -negative cases presented higher SPF than PPAR γ -positive cases ($P<0.05$). Graph with error bars indicate mean value \pm SEM.

Correlation between PPAR γ protein expression and ploidy. The correlation between PPAR γ protein expression and ploidy is summarised in Table III. In the whole series, PPAR γ -negative thyroid lesions were more frequently aneuploid (21 of 58; 36%) than PPAR γ -positive lesions (3 of 37; 8%) ($P=0.0031$). After excluding the PDTC/ATC subgroup, which presented aneuploidy in the vast majority of the cases, the difference was still statistically significant: 14 of 48 (29%) in PPAR γ -negative vs. 3 of 37 (8%) in PPAR γ -positive cases ($P=0.0268$). If nodular hyperplasias were excluded from the analysis the frequency of aneuploidy was still higher in PPAR γ -negative than in PPAR γ -positive tumours: 19 of 52 (37%) in PPAR γ -negative vs. 3 of 33 (9%) in PPAR γ -positive ($P=0.0052$).

Correlation between PPAR γ protein expression and SPF. PPAR γ -negative lesions presented higher SPF than PPAR γ -positive cases (PPAR γ -, $3.1\% \pm 0.4$; n=40 vs. PPAR γ +, $2.2\% \pm 0.2$; n=31; $P=0.0430$) (Fig. 3). This finding remained statistically significant considering only the neoplastic tissues (FTAs, FTCs, PTCs and PDTC) (PPAR γ -, $3.2\% \pm 0.4$; n=36 vs. PPAR γ +, $2.2\% \pm 0.2$; n=27; $P=0.0449$). However, it lost

Table III. Correlation between PPAR γ protein expression and ploidy.

Histotype (n)	PPAR γ immunohistochemistry Negative		Histotype (n)	PPAR γ immunohistochemistry Positive		P-value ^a
	Diploid (%)	Aneuploid (%)		Diploid (%)	Aneuploid (%)	
NH (n=6)	4 (67)	2 (33)	NH (n=4)	4 (100)	0 (0)	n.s.
FTA (n=16)	9 (56)	7 (44)	FTA (n=13)	11 (85)	2 (15)	n.s.
FTC (n=7)	5 (71)	2 (29)	FTC (n=2)	2 (100)	0 (0)	n.s.
PTC (n=19)	16 (84)	3 (16)	PTC (n=18)	17 (94)	1 (6)	n.s.
PDTC/ATC (n=10)	3 (30)	7 (70)	PDTC/ATC (n=0)	0 (0)	0 (0)	-
Total (n=58)	37 (64)	21 (36)	Total (n=37)	34 (92)	3 (8)	0.0031

^aFisher's exact test (PPAR γ immunostaining vs. ploidy); n, number of samples; n.s., non-significant.

significance when the PDTCs, which presented the highest SPF values, were removed (PPAR γ -, 2.5% \pm 0.3; n=32 vs. PPAR γ +, 2.2% \pm 0.2; n=31; P>0.05).

Discussion

In a previous study (22), we analysed the expression of PPAR γ in several types of thyroid lesions and observed that clinically aggressive tumours had lower PPAR γ protein expression than less aggressive carcinomas. Based on this finding, we hypothesized that low levels of PPAR γ expression might be correlated with lower expression of thyroid specific genes such as Tg, TSHR and NIS. Furthermore, since aneuploidy is more prevalent in poorly-differentiated thyroid carcinomas (26-28), we also investigated the correlation of PPAR γ expression with the ploidy status and the proliferative activity of thyroid lesions.

When all thyroid histotypes were grouped together, the levels of Tg mRNA were significantly lower in PPAR γ negative lesions than in cases staining for PPAR γ . The same was observed in the group of FTAs, which are benign tumours. Although not reaching statistical significance, the levels of TSHR and NIS mRNA were also lower in PPAR γ -negative than in PPAR γ -positive cases. These results suggest that loss of PPAR γ is related to a lower differentiation of thyroid follicular cells. This conforms well with the inhibition of cell proliferation and induction of apoptosis or cell differentiation which is observed in several types of cancers (8-11,15,29-35), following treatment with specific PPAR γ agonists. It is well known that the activation of PPAR γ suppresses the transcriptional activity of the E2F/DP complex (36). E2F is a transcription factor that regulates the expression of genes involved in entry into S phase and in DNA synthesis (37,38) and DP is an E2F-related protein that stabilizes E2F. According to Altioek *et al* (39) PPAR γ activation leads to a loss of binding of E2F/DP to DNA, due to an increase in phosphorylation of this complex. The action of PPAR γ on E2F/DP function may also be important at the level of cell differentiation. There are differentiation-promoting agents

that cause a decrease in the DNA-binding activity of E2F/DP complex, during the differentiation of several types of cells (40-43).

In general, aneuploid thyroid lesions presented higher SPF than diploid cases (5.7 \pm 0.8 vs. 2.2 \pm 0.1; P<0.0001) (Fig. 2). Higher proliferative activity has been found in thyroid carcinomas (FTCs and mixed follicular/papillary thyroid carcinomas) as compared to benign lesions (FTAs) and normal thyroid (44). Konarska *et al* (45) observed similar findings in three different thyroid tissues [colloid goiters, diploids (8.6%) vs. aneuploids (13.7%); parenchymatous goiters, diploids (3.7%) vs. aneuploids (6.7%); adenomas, diploids (8.4%) vs. aneuploids (10.2%)]. However, our SPF data should be considered with caution, since there is a lack of correlation with PPAR γ expression when the PDTC subgroup, which showed the highest SPF values, was excluded from the SPF analysis.

In our study, the PPAR γ -negative cases were more frequently aneuploid (Table III) and presented higher SPF (Fig. 3) than cases expressing PPAR γ . The molecular mechanism linking PPAR γ to ploidy of thyroid neoplasias remains largely unknown. However, the loss of PPAR γ expression may favour chromosomal instability because PPAR γ activation induces a block in the G₁-S transition by inhibiting RB (retinoblastoma) phosphorylation and by the attenuation of mitogen-induced p27 degradation (46-48).

An alternative hypothesis is that chromosomal instability could be the driving force that contributes to underexpression of PPAR γ and loss of expression of the thyroid-specific genes during the malignant progression of thyroid tumours.

In sum, our results showed that there is an association between underexpression of PPAR γ , aneuploidy, and lower cell differentiation of thyroid tumours. Therapies designed to modulate expression of PPAR γ may have an impact in tumour growth of thyroid neoplasias.

Acknowledgements

This study was supported by Fundação para a Ciência e Tecnologia (POCTI/CBO/48922/2002), Portugal.

References

- Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM and Fletcher JA: PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma (corrected). *Science* 289: 1357-1360, 2000. Erratum in: *Science* 289: 1474, 2000.
- Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG and Leite V: Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. *J Clin Endocrinol Metab* 87: 3947-3952, 2002.
- Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG and Nikiforov YE: PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. *Am J Surg Pathol* 26: 1016-1023, 2002.
- Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, Spiegelman B, Flier JS and Moller DE: Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. *J Clin Invest* 97: 2553-2561, 1996.
- Lefebvre AM, Laville M, Vega N, Riou JP, van Gaal L, Auwerx J and Vidal H: Depot-specific differences in adipose tissue gene expression in lean and obese subjects. *Diabetes* 47: 98-103, 1998.
- Rieusset J, Andreelli F, Auboeuf D, Roques M, Vallier P, Riou JP, Auwerx J, Laville M and Vidal H: Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor-gamma in human adipocytes. *Diabetes* 48: 699-705, 1999.
- Auwerx J: PPARgamma, the ultimate thrifty gene (Review). *Diabetologia* 42: 1033-1049, 1999.
- Elstner E, Müller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D and Koeffler HP: Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BXN mice. *Proc Natl Acad Sci USA* 95: 8806-8811, 1998.
- Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I and Koeffler HP: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. *Cancer Res* 58: 3344-3352, 1998.
- Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiock S, Oppenheim H, Evans RM and Spiegelman BM: Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. *Proc Natl Acad Sci USA* 94: 237-241, 1997.
- Ohta K, Endo T, Haraguchi K, Hershtman JM and Onaya T: Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. *J Clin Endocrinol Metab* 86: 2170-2177, 2001.
- Inoue K, Kawahito Y, Tsubouchi Y, Kohno M, Yoshimura R, Yoshikawa T and Sano H: Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. *Biochem Biophys Res Commun* 287: 727-732, 2001.
- Hase T, Yoshimura R, Mitsuhashi M, Segawa Y, Kawahito Y, Wada S, Nakatani T and Sano H: Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists. *Urology* 60: 542-547, 2002.
- Terashita Y, Sasaki H, Haruki N, Nishiwaki T, Ishiguro H, Shibata Y, Kudo J, Konishi S, Kato J, Koyama H, Kimura M, Sato A, Shinoda N, Kuwabara Y and Fujii Y: Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer. *Jpn J Clin Oncol* 32: 238-243, 2002.
- Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C and Spiegelman BM: Differentiation and reversal of malignant changes in colon cancer through PPARgamma. *Nat Med* 4: 1046-1052, 1998.
- Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, De la Chapelle A, Spiegelman BM and Eng C: Loss-of-function mutations in PPAR gamma associated with human colon cancer. *Mol Cell* 3: 799-804, 1999.
- Fabarius A, Willer A, Yerganian G, Hehlmann R and Duesberg P: Specific aneusomies in Chinese hamster cells at different stages of neoplastic transformation, initiated by nitrosomethylurea. *Proc Natl Acad Sci USA* 99: 6778-6783, 2002.
- Oyama T, Vickery AL Jr, Pfeffer FI and Colvin RB: A comparative study of flow cytometry and histopathologic findings in thyroid follicular carcinomas and adenomas. *Hum Pathol* 25: 271-275, 1994.
- Hostetter AL, Hrafnkelsson J, Wingren SO, Enestrom S and Nordenskjöld B: A comparative study of DNA cytometry methods for benign and malignant thyroid tissue. *Am J Clin Pathol* 89: 760-763, 1988.
- Soares P and Sobrinho-Simões M: Recent advances in cytometry, cytogenetics and molecular genetics of thyroid tumours and tumour-like lesions (Review). *Pathol Res Pract* 191: 304-317, 1995.
- Francia G, Azzolina L, Mantovani T, Daví MV, Brazzarola P, Valerio A, Petronio R and Sussi P: Heterogeneity of nuclear DNA pattern and its relationship with cell cycle activity parameters in multinodular goitre. *Clin Endocrinol (Oxf)* 46: 649-654, 1997.
- Marques AR, Espadinha C, Frias MJ, Roque L, Catarino AL, Sobrinho LG and Leite V: Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours. *Br J Cancer* 91: 732-738, 2004.
- Sugg SL, Ezzat S, Rosen IB, Freeman JL and Asa SL: Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. *J Clin Endocrinol Metab* 83: 4116-4122, 1998.
- Deitch AD, Law H and De Vere White R: A stable propidium iodide staining procedure for flow cytometry. *J Histochem Cytochem* 30: 967-972, 1982.
- Dean PN and Jett JH: Mathematical analysis of DNA distributions derived from flow microfluorometry. *J Cell Biol* 60: 523-527, 1974.
- Joensuu H, Kleim P, Eerola E and Tuominen J: Influence of cellular DNA content on survival in differentiated thyroid cancer. *Cancer* 58: 2462-2467, 1986.
- Joensuu H and Kleim PJ: Comparison of nuclear DNA content in primary and metastatic differentiated thyroid carcinoma. *Am J Clin Pathol* 89: 35-40, 1988.
- Sturgis CD, Caraway NP, Johnston DA, Sherman SI, Kidd L and Katz RL: Image analysis of papillary thyroid carcinoma fine-needle aspirates: significant association between aneuploidy and death from disease. *Cancer* 87: 155-160, 1999.
- Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM and Singer S: Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. *Proc Natl Acad Sci USA* 96: 3951-3956, 1999.
- Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S and Spiegelman BM: Terminal differentiation of human breast cancer through PPAR gamma. *Mol Cell* 1: 465-470, 1998.
- Brockman JA, Gupta RA and Dubois RN: Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. *Gastroenterology* 115: 1049-1055, 1998.
- Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S and Matsuzawa Y: Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. *Jpn J Cancer Res* 90: 75-80, 1999.
- Guan YF, Zhang YH, Breyer RM, Davis L and Breyer MD: Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. *Neoplasia* 1: 330-339, 1999.
- Chang TH and Szabo E: Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. *Cancer Res* 60: 1129-1138, 2000.
- Motomura W, Okumura T, Takahashi N, Obara T and Kohgo Y: Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27Kip1 in human pancreatic carcinoma cells. *Cancer Res* 60: 5558-5564, 2000.
- Fajas L, Debril MB and Auwerx J: Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis (Review). *J Mol Endocrinol* 27: 1-9, 2001.
- Zheng L and Lee WH: The retinoblastoma gene: a prototypic and multifunctional tumor suppressor (Review). *Exp Cell Res* 264: 2-18, 2001.
- DiCiommo D, Gallie BL and Bremner R: Retinoblastoma: the disease, gene and protein provide critical leads to understand cancer (Review). *Semin Cancer Biol* 10: 255-269, 2000.

39. Altioek S, Xu M and Spiegelman BM: PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. *Genes Dev* 11: 1987-1998, 1997.
40. La Thangue NB and Rigby PW: An adenovirus E1A-like transcription factor is regulated during the differentiation of murine embryonal carcinoma stem cells. *Cell* 49: 507-513, 1987.
41. Hara E, Okamoto S, Nakada S, Taya Y, Sekiya S and Oda K: Protein phosphorylation required for the formation of E2F complexes regulates N-myc transcription during differentiation of human embryonal carcinoma cells. *Oncogene* 8: 1023-1032, 1993.
42. Melamed D, Tiefenbrun N, Yarden A and Kimchi A: Interferons and interleukin-6 suppress the DNA-binding activity of E2F in growth-sensitive hematopoietic cells. *Mol Cell Biol* 13: 5255-5265, 1993.
43. Kranenburg O, De Groot RP, van der Eb AJ and Zantema A: Differentiation of P19 EC cells leads to differential modulation of cyclin-dependent kinase activities and to changes in the cell cycle profile. *Oncogene* 10: 87-95, 1995.
44. Harlow SP, Duda RB and Bauer KD: Diagnostic utility of DNA content flow cytometry in follicular neoplasms of the thyroid. *J Surg Oncol* 50: 1-6, 1992.
45. Konarska L, Skierski J, Ellert A, Steinbrich J, Wozniak A and Kalczak M: Comparative studies of nuclear DNA content in benign and malignant thyroid lesions. *Acta Biochim Pol* 48: 783-793, 2001.
46. Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA and Law RE: Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1→S transition in vascular smooth muscle cells. *J Biol Chem* 275: 22435-22441, 2000.
47. Chung SH, Onoda N, Ishikawa T, Ogisawa K, Takenaka C, Yano Y, Hato F and Hirakawa K: Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells. *Jpn J Cancer Res* 93: 1358-1365, 2002.
48. Martelli ML, Iuliano R, Le Pera I, Sama' I, Monaco C, Cammarota S, Kroll T, Chiariotti L, Santoro M and Fusco A: Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. *J Clin Endocrinol Metab* 87: 4728-4735, 2002.